25.9 months; HR, 0.75 [95% CI, 0.64–0.88]).[74]The incidences of thrombocytopenia and increased serum aminotransferase levels were higher in patients who received T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar syndrome were higher in patients who received lapatinib plus capecitabine.
Median PFS was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (HR, 0.65; 95% CI, 0.55–0.77;P< .001).
Median OS was longer with T-DM1 versus lapatinib plus capecitabine (29.9 months vs.
25.9 months; HR, 0.75 [95% CI, 0.64–0.88]).[74] The incidences of thrombocytopenia and increased serum aminotransferase levels were higher in patients who received T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar syndrome were higher in patients who received lapatinib plus capecitabine.